3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Breast Neoplasms
14
Polycystic Ovary Syndrome
9
Neoplasms
5
Endometrial Neoplasms
3
Prostatic Neoplasms
2
Peripheral Nervous System Diseases
2
Obesity
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Melanoma
2
Leukemia, Myeloid, Acute
2
Leiomyoma
2
Insulin Resistance
2
Inflammation
2
Infertility, Female
2
Glioblastoma
2
Diabetes Mellitus
2
Colorectal Neoplasms
2
Cognitive Dysfunction
2
Cardiotoxicity
2
Weight Gain
1
Vomiting
1
Venous Thromboembolism
1
Vascular Malformations
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Triple Negative Breast Neoplasms
1
Thrombocythemia, Essential
1
Stem Cell Transplant Complications
1
Interventions
Cyclophosphamide
72
fludarabine phosphate
64
Peripheral Blood Stem Cell Transplantation
64
Busulfan
50
Cyclosporine
48
Mycophenolic Acid
45
Tacrolimus
41
Antilymphocyte Serum
41
Radiotherapy
37
Whole-Body Irradiation
33
Methotrexate
33
Filgrastim
33
Imatinib Mesylate
27
Methylprednisolone
25
Cord Blood Stem Cell Transplantation
24
Melphalan
22
Dasatinib
16
sargramostim
15
Etoposide
15
nilotinib
14
Cytarabine
14
Interferon-alpha
13
Therapeutics
11
Flow Cytometry
11
Cyclosporins
11
Thiotepa
9
Sirolimus
9
Alemtuzumab
9
Polymerase Chain Reaction
8
Psychiatric Rehabilitation
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Leukemia, Myeloid, Chronic-Phase
×
Tablets
×
Clear all
NCT01827930
2020-12-31
MIM
Institut Bergonié
Phase 3
Terminated
68 enrolled
13 charts